Physician profile
Maxwell Reback
NPI 1700271905
$1,468.53
in general payments reported to CMS, 2019-2025
21 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $382 · 2022: $33.56 · 2023: $76.56 · 2024: $340 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.69 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $257.67 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $226.87 | 2020-2024 | |
| Glaxosmithkline, LLC. | $219.93 | 2024-2025 | Nucala, Trelegy Ellipta |
| Karyopharm Therapeutics INC. | $176.91 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $119.95 | 2019 | |
| Harmony Biosciences LLC | $106.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $57.87 | 2023-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $31.33 | 2024 | Opsumit |
| Philips North America LLC | $29.39 | 2025 | Vest Therapy Und |
| Verona Pharma, INC. | $28.38 | 2025 | Ohtuvayre |
| Amgen INC. | $24.70 | 2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.50 | 2025 | Jascayd |
| Electromed, INC. | $23.21 | 2025 | Smartvest |
| Eisai INC. | $22.99 | 2020 | |
| Mallinckrodt Hospital Products INC. | $20.45 | 2025 | Acthar |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.08 | 2020 | |
| Abbvie INC. | $18.59 | 2024 | |
| Daiichi Sankyo INC. | $17.25 | 2020 | |
| United Therapeutics Corporation | $16.37 | 2024 | |
| Insmed, INC. | $14.50 | 2025 | Arikayce |
| Pharmacyclics LLC, An Abbvie Company | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Reback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.